Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

48.87 -3.55 (-6.78%)
Delayed Quote Updated: 2:14 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere (TVTX) Q3 2026 Earnings Call Transcript ↗
FILSPARI sales hit $200.2 million as FSGS launches alongside sustained IgAN demand. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call ↗
Travere Therapeutics (NASDAQ:TVTX) reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its... 
Via MarketBeat
Topics Earnings
Travere Therapeutics (NASDAQ:TVTX) Revenue Beat Offset by Wider-Than-Expected Loss ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) Beats Q2 Revenue Estimates on FILSPARI Sales Growth ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) Earns Perfect Ratings in Breakout Setup Screen ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup ↗
Via Chartmill
News headline image
Travere Therapeutics Reports Third Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Third Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics (NASDAQ:TVTX) - High Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
News headline image
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Announces Planned Chief Executive Officer Transition
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline ↗
Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building... 
Via MarketBeat
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript ↗
FILSPARI net sales surged 96% year-over-year, driven by strong FSGS launch demand. 
Via The Motley Fool
Topics Earnings
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Q2 Earnings Call Highlights ↗
Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental... 
Via MarketBeat
Topics Earnings
News headline image
Travere Therapeutics Reports Second Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Second Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
From Travere Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.